It was great to join the Convenzis team again for the patient flow event. As always, the team were incredibly accommodating and happy to help. The quality of attendees is always of a high standard and relevant to the patient flow and to us also. We continue to have great discussions and footfall around our stand with no need to try and encourage people to come and see us. Really positive event for us and we look forward to working with Convenzis in the future.
Dr Anguraj Sadanandam
Team Leader
The Institute of Cancer Research
Dr. Sadanandam is a Director, Centre for Global Oncology and Reader in Stratified and Precision Medicine at the Institute of Cancer Research (ICR), London. He is currently applying his multidisciplinary skills to the integrated science of stratified medicine to understand cell-of-origin, inter- and intra-tumoral/immune/stromal heterogeneity, and test precise therapies for different subtypes of GI cancers. To this point, his team develops and applies primarily AI/ML approaches that generate hypotheses to validate further using experimental biology (pre-clinical models) and clinical studies (by profiling clinical samples and developing companion diagnostics).
Dr. Sadanandam led/co-led the research work to define transcriptome/multi-omics subtypes of pancreatic, colorectal, gastroesophageal, and breast cancers associated with prognosis and potential personalized therapies (multiple high-impact publications). These subtypes and classifications are highly cited and applied by the clinical research communities. He contributes to various consortia and clinical studies, including ColoRectal Cancer Subtyping Consortium (CRCSC in 2015), COLOSSUS consortium (EU), and the Indian Cancer Genome Atlas (ICGA) project (Founding Member).
Dr. Sadanandam initiated the Centre for Global Oncology at the ICR to enhance cancer research and clinical data orchestration in low-middle income countries (LMIC; including India) and avoid disparity in research. He is a part of an international multidisciplinary tumor board and currently exploring entrepreneurship opportunities to translate his findings to the clinic in LMIC and high-income countries.
